Riskpilot← Back to searchSign inGet full accessSoflin Pharma AB
ABActiveOrg 5569404477StockholmWholesale of other food · NACE 4638Est. 20133 employees
Revenue 2025
SEK 13,5M
+22% vs 2024
EBITDA margin
34.7%
+35% vs 2024
Equity ratio
62.1%
Financial strength
Net profit 2025
SEK 3,8M
+86% vs 2024
| Revenue | SEK 13,5M | +22% |
| EBITDA | SEK 4,7M | +35% |
| Net profit | SEK 3,8M | +86% |
| Total assets | SEK 10,2M | +32% |
| Equity | SEK 6,4M | +95% |
| Employees | 3 | — |
Legal name
Soflin Pharma AB
Org number
5569404477
Legal form
Aktiebolag
NACE code
4638 · Wholesale of other food
Founded
27 augusti 2013
Share capital
SEK 50 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva handel med samt forskning, utveckling och konsultverksamhet inom kosttillskott, livsmedel, läkemedel och medicintekniska produkter. Bolaget skall även äga och förvalta värdepapper och fastigheter.
Address
Stockholm
Email
info@soflinpharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 369 | 8 733 | 9 672 | 11 036 | 13 468 |
| Staff expenses | — | −926 | −2 183 | −1 901 | — |
| EBITDA | 1 807 | 2 066 | 2 066 | 3 452 | 4 667 |
| Depreciation & amort. | −39 | −39 | −100 | −138 | −317 |
| EBIT | 1 768 | 2 028 | 1 965 | 3 315 | 4 350 |
| Net financials | −445 | −484 | −77 | 23 | 197 |
| Profit before tax | 1 089 | 1 024 | 1 988 | 2 617 | 4 788 |
| Tax | −287 | −323 | −450 | −569 | −978 |
| Net profit | 802 | 701 | 1 538 | 2 048 | 3 810 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 565 | 4 359 | 6 192 | 7 751 | 10 240 |
| Equity | 1 124 | 1 325 | 1 963 | 3 261 | 6 357 |
| Long-term debt | 0 | — | — | — | 0 |
| Short-term debt | 2 092 | 1 165 | 2 459 | 2 000 | 1 633 |
| Total debt | 2 092 | 1 165 | 2 459 | 2 000 | 1 633 |
EBITDA margin
34.7%
This company
15.8%
Market median
+120% vs market
20212025
Equity ratio
62.1%
This company
38.2%
Market median
+63% vs market
20212025
Return on equity
59.9%
This company
18.4%
Market median
+226% vs market
20212025
Net profit margin
28.3%
This company
8.1%
Market median
+249% vs market
20212025
Asset turnover
1.32×
This company
1.12×
Market median
+18% vs market
20212025
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Audit | 2022 | |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Soflin Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Johan Erik Eriksson Isbrand | Audit | 0 companies |
| Anders Johan Strömstedt | Board of Directors | 0 companies |
| Anders Stefan Niclas Strömstedt | Deputy Board Member | 0 companies |
| Anna Sofie Strömstedt | Deputy Board Member | 0 companies |